Details for Patent: 12,290,700
✉ Email this page to a colleague
Which drugs does patent 12,290,700 protect, and when does it expire?
Patent 12,290,700 protects LEVULAN and is included in one NDA.
This patent has fifteen patent family members in seven countries.
Summary for Patent: 12,290,700
| Title: | Adjustable illuminator for photodynamic therapy and diagnosis |
| Abstract: | An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration. |
| Inventor(s): | Thomas Boyajian, Mark Carota, Brian Mazejka |
| Assignee: | Sun Pharmaceutical Industries Inc |
| Application Number: | US17/889,115 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,290,700
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | RX | Yes | Yes | 12,290,700 | ⤷ Start Trial | TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,290,700
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018250595 | ⤷ Start Trial | |||
| Australia | 2023285927 | ⤷ Start Trial | |||
| Australia | 2026203479 | ⤷ Start Trial | |||
| Canada | 3057840 | ⤷ Start Trial | |||
| European Patent Office | 3362145 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
